Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma.

ABSTRACT:

Background

Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy with a poor prognosis. No efficacious treatment options are currently available for patients with advanced metastatic disease with disease progression to standard etoposide, doxorubicin, cisplatin and mitotane (EDP-M) therapy. We assessed the activity and tolerability of cabazitaxel as a second/third-line approach in metastatic ACC.

Patients and methods

Patients included in this single-center, phase II study (ClinicalTrials.gov identifier NCT03257891) had disease progression to a cisplatin-containing regimen (such as EDP) plus mitotane, plus/minus a further chemotherapy line. Cabazitaxel was administered intravenously at 25 mg/m² on day 1 of a 21-day cycle, for a maximum of six cycles. T

SUBMITTER: Lagana M 

PROVIDER: S-EPMC9058897 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature